All In Biotech

Drug Trial Radar · NCT03353753

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies

Last checked: Nov 19, 2026Latest source record: Nov 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

129

Actual

Start

Feb 27, 2018

Primary completion

May 31, 2019

Study completion May 11, 2022

Sponsor

Lead sponsor
Deciphera Pharmaceuticals, LLCIndustry
Sponsor type
Industry
First posted
Nov 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-arm, randomized, placebo-controlled, double-blind, international, multicenter study comparing the efficacy of ripretinib (DCC-2618) to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients were randomized in a 2:1 ratio to ripretinib 150 mg QD or placebo

Conditions

  • Gastrointestinal Stromal Tumors

Interventions

  • DCC-2618Drug

    Oral KIT/PDGFRA kinase inhibitor

  • Placebo Oral TabletDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From date of randomization to the earliest date of disease progression or death from any cause [through database cutoff 31-May-2019 (up to approximately 15 months)].

Locations

35 sites in 13 countries. Site status is shown where the registry gives one.

  • HonorHealth

    Scottsdale, Arizona

  • University of Southern California - Norris

    Los Angeles, California

  • UCLA

    Los Angeles, California

  • Stanford

    Stanford, California

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Georgia Cancer Specialists

    Atlanta, Georgia

  • University of Chicago

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Columbia

    New York, New York

  • MSKCC

    New York, New York

  • Oregon Health & Science University

    Portland, Oregon

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • MD Anderson Cancer Center

    Houston, Texas

  • Alfred University

    Melbourne, Australia

  • University Hospital Leuven

    Leuven, Belgium

  • Princess Margaret Hospital

    Toronto, Canada

  • Cross Cancer Center

    Edmonton, Alberta, Canada

  • Helsinki University Central Hospital

    Helsinki, Finland

  • Institut Bergonié

    Bordeaux, France

  • Le Centre Léon Bérard

    Lyon, France

  • Gustave-Roussy

    Villejuif, France

  • Sarcoma Center Brandenburg

    Brandenburg, Germany

  • University Hospital Essen

    Essen, Germany

  • Universitätsmedizin Mannheim

    Mannheim, Germany

  • Istituto Nazionale dei Tumori

    Milan, Italy

  • Università Campus Bio-Medico di Roma

    Rome, Italy

  • Leiden University Medical Center

    Leiden, Netherlands

  • Maria Sklodowska-Curie Memorial Cancer Center

    Warsaw, Poland

  • NCC

    Singapore, Singapore

  • Vall d'Hebron

    Barcelona, Spain

  • Hospitalario Universitario Virgen del Rocío

    Seville, Spain

  • Royal Marsden

    London, United Kingdom

  • University of Sheffield

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.